328548-32-9Relevant academic research and scientific papers
Synthesis, spectroscopic characterization and pharmacological evaluation of oxazolone derivatives
Fareed, Ghulam,Afza, Nighat,Versiani, Muhammad Ali,Fareed, Nazia,Mughal, Uzma Rasheed,Kalhoro, Mahboob Ali,Iqbal, Lubna,Lateef, Mehreen
, p. 1127 - 1134 (2013)
A series of six 4-(arylmethylidene)-2-phenyl/methyl-5(4H)-oxazolone derivatives were synthesized using a reported method by condensation of aldehydes with N-benzoyl/N-acetyl glycine in the presence of zinc oxide as a catalyst and acetic anhydride at room temperature in ethanol. Five of the compounds are new derivatives. The structures of the compounds were evaluated based on 1H-NMR, 13C-NMR, EI-MS and FT-IR spectroscopy and elemental analysis. All the compounds were screened for their antibacterial and urease inhibition activity. The antibacterial activity was tested by the agar well diffusion method using Mueller-Hinton agar medium. Compound 2 showed excellent activity against Staphylococcus aureus exhibiting 16 mm (80 %) inhibition and above 24 mm (70 %) against Salmonella typhi. Compound 6 was the most active compound against Escherichia coli having 20 mm (80 %) inhibition followed by compound 5 having above 18 mm (70 %) inhibition. Urease inhibition activity of all the compounds was determined by the indophenol method. Compounds 3, 6 and 7 showed significant inhibition against Jack bean urease.
Antileshmanial activities of synthetic substituted 2-phenyl-4-[phenylmethylidene]-1,3-oxazol-5(4H)-ones
Khan, Saadia Razi,Ghouri, Nida,Karim, Aneela,Naz, Farzana,Fakhri, Muhammad Imran,Perveen, Shahnaz,Khan, Khalid Mohammed,Taha, Muhammad,Choudhary, Muhammad Iqbal
, p. 980 - 985 (2016/01/12)
Substituted 2-phenyl-4-[phenylmethylidene]-1,3-oxazol-5(4H)-ones 1-27 were evaluated for their activity against Leishmania major. Compounds 1-27 demonstrated in vitro antileishmanial activities with IC50 values between 28.9 - 69.05 μM, as compared to standard drug pentamidine (IC50 = 5.09 ± 0.04 μM). Compounds 12 (IC50 = 28.90 ± 1.10 μM), 24 (IC50 = 31.4 ± 2.15 μM), 13 (IC50 = 35.0 ± 3.18 μM), 16 (IC50 = 35.0 ± 3.13 μM), and 25 (IC50 = 35.0 ± 3.18μM) displayed signifiant antileishmanial activities. Whereas, compounds 8-10, 15, 19, and 26 with IC50 values of 62.2 ± 3.36, 57.8 ± 2.30, 57.72 ± 5.02, 56.18 ± 4.40, 57.85 ± 2.25, 69.05 ± 6.20, 54.8 ± 1.50, and 57.8 ± 2.30 μM showed a moderate antileishmanial activities.
